Nanotronics Health, LLC, also received authorization for the nHale to be used with supplemental oxygen under a doctor's prescription.
As knowledge of the disease progresses, medical professionals and the public have become aware of how crucial non-invasive ventilation is for COVID-19 patient care in the hospital and beyond.
To meet this need, Nanotronics Health, LLC, leveraged Nanotronics' deep in-house expertise, incorporating advanced AI, Intelligent Factory Control and sophisticated engineering to conceive, design and manufacture the noninvasive ventilator in under 90 days.
nHale is accessible to patients at a fraction of the cost of other noninvasive ventilators. With a one-button approach, the device is designed for quality, comfort, and ease of use.
Nanotronics Health, LLC, developed and designed nHale to assist spontaneously breathing adults suffering from COVID-19 disease.
It is intended for use in non-life-threatening situations, such as a patient in need of breathing assistance but not in need of invasive ventilatory support based on standard medical protocols.
Nanotronics Health, LLC is a subsidiary of and powered by Nanotronics. The company uses Intelligent Factory Control to build and scale medical devices that are affordable, accessible and well-designed.
Our first product, nHale, a non-invasive ventilator, was conceived, built, and obtained Emergency Use Authorization by the FDA within 90 days to treat patients suffering from COVID-19.
After obtaining Emergency Use Authorization, Nanotronics immediately began producing and shipping devices.
The nHale is a bi-level positive air pressure device to support respiratory therapy of spontaneously breathing adults weighing over 30kg suffering from COVID-19 disease.
It is a non-invasive ventilator designed to be used in non-life-threatening situations, for spontaneously breathing patients, such as a patient in need of breathing assistance but not in need of invasive ventilatory support based on standard medical protocols.
The machine is for use in traditional healthcare facilities (e.g., hospitals, assisted living facilities, nursing homes) as well as spaces converted for the care of large numbers of COVID-19 patients (e.g., convention centers, university dormitories, motels, etc.).
The nHale is also intended for use in home settings with a doctor's prescription.
Supplemental oxygen may be used with the nHale device to increase the oxygen concentration of the airflow being delivered to the patient only when prescribed and trained by a qualified medical professional.
The warnings must be observed when using supplemental oxygen with the nHale device.
Nanotronics Health LLC, a subsidiary of Nanotronics, applied Nanotronics' deep in-house expertise, incorporating advanced AI, Intelligent Factory Control, and sophisticated engineering to build a machine that is easily manufactured at scale and at a reduced cost to increase accessibility for all Americans.
The nHale device is designed for comfort and ease-of-use with the simplicity of one button.
nHale has been authorized by FDA under an Emergency Use Authorization [EUA]; nHale is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of the device; nHale has not been FDA cleared or approved.
Circio unveils circVec proof-of-concept
GSK releases decade-long data on Shingrix efficacy
BiVictriX receives FDA Orphan Drug Designation for AML treatment candidate
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
GSK's meningitis vaccine candidate accepted for FDA review
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
ProAxsis secures GBP1.8m investment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients